Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Targeted therapy for AML

Juliette Lambert • 30 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Antibodies Gemtuzumab ozogamicin

Juliette Lambert, MD, Versailles Hospital, Le Chesnay, France, talks on treatment options for acute myeloid leukemia (AML), including gemtuzumab ozogamicin. Dr Lambert highlights the importance of finding the place for gemtuzumab ozogamicin among targeted therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Juliette Lambert

2:43
Gemtuzumab ozogamicin in frontline AML therapy
Juliette Lambert • 30 Jun 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals